Sumitomo Pharma
Tracked across 4 events · 24 articles · First seen Mar 06, 2026 · Last active Jun 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Impact: Sumitomo Pharma received conditional and time-limited approval for its Parkinson's disease treatment, Amchepry, which is expected to be the world's first commercially available iPS cell product. This approval significantly boosts the company's market position in regenerative medicine.
Mar 06, 2026 · 6 articles
Business
The Japanese stock market, as measured by the Nikkei 225, experienced a period of significant volatility and overall decline across multiple trading days. This downturn was largely influenced by negative cues from The Wall Street…
Impact: Sumitomo Pharma's stock slipped, indicating a negative trend for the company.
May 18, 2026 · 6 articles
Business
Poxel>>>, a biopharmaceutical company, announced the appointment of Yves Decadt>>> as its new Chief Executive Officer, effective June 10, 2026. He succeeds Nicolas Trouche>>>, who oversaw the company's restructuring period since August 2025 and the…
Impact: Sumitomo Pharma>>> markets Imeglimin, a drug from Poxel>>>, in Japan for type 2 diabetes, demonstrating the drug's clinical efficacy and commercial potential.
Jun 10, 2026 · 6 articles
Domestic
The Japanese stock market, as measured by the Nikkei 225, experienced sharp gains across several trading sessions, extending previous rallies. This positive trend was largely influenced by broadly positive cues from Wall Street, where the…
Impact: Sumitomo Pharma declined more than 3 percent in one trading session.
May 21, 2026 · 6 articles
NEWSDESK
Track Sumitomo Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard